BIOTRONIK SE & Co. KG
Biotronik's Portuguese subsidiary selling cardiovascular medical devices.
Last updated November 4, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
BIOTRONIK SE & Co. KG is a privately held German medical-technology company headquartered in Berlin. The company develops, manufactures, and supports devices and digital systems used to diagnose, treat, and monitor cardiovascular disease, cardiac rhythm disorders, and selected chronic-pain conditions. Its principal areas are cardiac rhythm management, remote patient monitoring, electrophysiology, and neuromodulation. The company has historically also operated a substantial vascular-intervention business, although that business was transferred to Teleflex effective July 1, 2025. BIOTRONIK traces its origins to 1963, when physicist Max Schaldach and electrical engineer Otto Franke developed the first German implantable pacemaker at Technische Universität Berlin. Their early IP-3 pacemaker emphasized lower energy consumption and reduced weight compared with contemporary devices. The company’s founding technology established a long-term focus on making electronic therapy systems compatible with the human body, while also building in-house capabilities in electronics, sensors, leads, software, manufacturing, and clinical support. During the 1970s and 1980s, BIOTRONIK expanded its manufacturing and international presence. It established a production operation in Lake Oswego, Oregon, following the acquisition of the American pacemaker producer Stimulation Technology, and developed increasingly sophisticated pacing systems. Its work on dual-chamber stimulation contributed to devices that could sense atrial activity and coordinate ventricular pacing more naturally. BIOTRONIK subsequently broadened its portfolio beyond pacemakers. In 1993 it produced the first German implantable cardioverter-defibrillator, and it developed technologies such as closed-loop stimulation and fractal electrode coatings to improve sensing, stimulation, and physiological responsiveness. The company added electrophysiology products in 1994 and vascular-intervention products in 1995. This created a broad cardiovascular portfolio covering pacemakers, implantable cardioverter-defibrillators, cardiac-resynchronization systems, diagnostic and ablation catheters, coronary and peripheral stents, balloon catheters, guidewires, and supporting equipment. Its Philos pacemaker family, introduced with telemetry and CE Mark approval in 2000, was associated with the company’s early deployment of remote monitoring. BIOTRONIK Home Monitoring enabled implanted devices to transmit clinically relevant information outside the hospital or physician’s office, helping clinicians detect arrhythmias and other changes earlier. Connected care became a major part of the company’s positioning. The BioMonitor family provided long-term implantable ECG monitoring and remote data collection, while CardioMessenger devices connected implanted cardiac systems to BIOTRONIK’s Home Monitoring infrastructure. The company also developed ProMRI technology for selected pacemaker, defibrillator, and lead combinations, allowing eligible patients to undergo MRI examinations under specified conditions. Online configuration and compatibility tools were later introduced to help clinicians verify MRI conditions for individual systems. BIOTRONIK’s vascular-intervention business included coronary drug-eluting stents, covered stents, bioresorbable or bio-absorbable technologies, peripheral stents, angioplasty balloons, drug-coated balloons, guidewires, and access products. Product families such as Orsiro, PK Papyrus, Pantera Lux, Passeo-18 Lux, Astron, Pulsar, and Fortress became associated with this part of the business. In February 2025, BIOTRONIK announced a strategic refocusing on active implantable devices and digital health, including connected-care platforms, remote monitoring, and artificial-intelligence-enabled capabilities. Teleflex completed the acquisition of substantially all of BIOTRONIK’s Vascular Intervention business on July 1, 2025; the transferred portfolio included major coronary and peripheral products, while some products were excluded from the transaction. In 2023, BIOTRONIK entered neuromodulation through FDA approval of the Prospera spinal cord stimulation system in the United States and launched the BIOTRONIK Neuro business segment. Prospera combines spinal-cord stimulation with remote monitoring and a support model intended for people with chronic, intractable pain. The move broadened the company’s addressable market beyond cardiovascular medicine while retaining its historical emphasis on implanted electrical therapies and remote care. BIOTRONIK remains a global specialist medical-device manufacturer with operations, manufacturing, research, training, and commercial activities across Europe, North America, Asia, Latin America, and other markets. Its current strategic identity centers on active implantable therapies, cardiac rhythm management, electrophysiology, digital monitoring, and neuromodulation. The company has also faced significant compliance and legal criticism in the United States, including settlements over allegations that improper payments and benefits were provided to physicians to influence device use. Those matters remain an important part of the brand’s corporate and regulatory history.
History
BIOTRONIK began in Germany in 1963 after physicist Max Schaldach and electrical engineer Otto Franke developed the country’s first implantable pacemaker at Technische Universität Berlin. Their IP-3 device was designed to use less energy and weigh less than many contemporary pacemakers. In late 1963, surgeon Prof. Emil Sebastian Bücherl implanted the device in a patient. The founding project established the company’s core technical identity: combining electronics, sensing, and implanted therapy in a form that could operate reliably inside the human body. The company’s early development concentrated on increasing pacemaker capability, extending battery life, and improving the electrical connections among the generator, leads, and heart. In 1976, BIOTRONIK moved to a facility in Sieversufer in Berlin’s Britz district. In 1979, it established a production site in Lake Oswego, Oregon, through the acquisition of the American pacemaker manufacturer Stimulation Technology. The U.S. presence later became an important part of BIOTRONIK’s international manufacturing and commercial infrastructure. During the 1980s, BIOTRONIK worked on dual-chamber stimulation. This approach allowed a pacemaker to sense atrial activity and coordinate ventricular stimulation more closely with the patient’s own cardiac rhythm. The Diplos 03, a multi-programmable DDD pacemaker with bilateral telemetry, helped strengthen the company’s presence in Europe, South America, and Asia. In 1987, the company moved its headquarters to Woermannkehre 1 in Berlin, the address that remains associated with its principal corporate site. In 1993, BIOTRONIK produced the first German implantable cardioverter-defibrillator, including the Phylax 06. The company also developed closed-loop stimulation, a method intended to make pacing respond to changes in the patient’s physiological state. In the same period, it introduced fractal coating for implantable electrodes. The coating increased the electrically active surface and was intended to improve sensing and stimulation performance. These developments marked BIOTRONIK’s evolution from a pacemaker producer into a broader cardiac-rhythm-management company. BIOTRONIK entered electrophysiology in 1994 and vascular intervention in 1995. Electrophysiology expanded the portfolio into diagnostic catheters, ablation systems, mapping-related equipment, and other tools used to investigate and treat abnormal heart rhythms. Vascular intervention added balloon catheters, coronary and peripheral stents, guidewires, covered stents, drug-coated balloons, and related products used in the treatment of arterial disease. The Philos family received CE Mark approval in 2000 and represented a complete telemetry-enabled pacemaker range. Around the same period, BIOTRONIK implanted a pacemaker connected to its Home Monitoring concept. Home Monitoring became one of the company’s most distinctive technologies, allowing information from implanted devices to be transmitted to healthcare professionals between scheduled visits. The system supported earlier detection of clinically relevant events and helped establish remote monitoring as a central component of modern implanted-device care. In 2010, BIOTRONIK introduced the Lumax 540 VR-T DX, described by the company and reference material as a single-chamber defibrillator with extensive atrial diagnostics. The company also formed an international distribution arrangement with Endosense for the TactiCath ablation catheter. In 2011, BIOTRONIK launched Orsiro, a drug-eluting coronary stent using a bio-absorbable coating. Orsiro became one of the best-known products in the company’s vascular-intervention range. The following years brought further expansion in monitoring and imaging compatibility. BIOTRONIK launched BioMonitor, an implantable miniaturized ECG-monitoring device designed for continuous monitoring and remote data collection. It also developed ProMRI systems that allowed certain pacemaker, defibrillator, and lead combinations to be used during MRI scanning under specified conditions. The company later introduced ProMRI SystemCheck and ProMRI Configurator tools to help clinicians verify system compatibility and scanning requirements. In 2012, BIOTRONIK acquired Berlin’s historic Postfuhramt building on Oranienburger Strasse. In 2014, it launched Passeo-18 Lux, a drug-coated balloon for peripheral artery disease of the lower limbs. In 2015, it introduced CardioMessenger Smart as a newer patient communication device for Home Monitoring and BioMonitor 2 as the second generation of its insertable cardiac-monitor platform. The company opened an Education and Innovation Center in New York City in 2016, expanded high-technology manufacturing in Singapore, and adopted the “Excellence for Life” brand promise in 2017. BIOTRONIK’s corporate history also includes major compliance controversies. In 2014, the U.S. Department of Justice announced a $4.9 million settlement resolving allegations that the company used improper payments, meals, and inflated advisory-board compensation to influence physicians’ use of its cardiac devices. In 2022, the department announced a second settlement of $12.95 million involving allegations concerning physician payments, training programs, lavish events, travel, and honoraria. Both matters were civil settlements of allegations rather than findings of criminal liability, but they created substantial reputational and compliance concerns. In 2023, BIOTRONIK entered neuromodulation after receiving FDA approval for Prospera, a spinal cord stimulation system for chronic, intractable pain. The approval launched BIOTRONIK Neuro and extended the company’s experience with implantable electrical therapies and remote monitoring into the pain-treatment market. In February 2025, BIOTRONIK announced a strategic shift toward active implantable devices and digital health. The company agreed to divest its Vascular Intervention business to Teleflex. Teleflex completed the transaction effective July 1, 2025, acquiring substantially all of the business and a portfolio that included coronary and peripheral products such as Orsiro, Pantera Lux, PK Papyrus, Passeo-18 Lux, Astron, Pulsar, and related systems. The transaction reduced BIOTRONIK’s exposure to interventional vascular products and sharpened its focus on cardiac rhythm management, implantable monitoring, electrophysiology, neuromodulation, and connected-care technologies.
- 2025
Vascular Intervention business transferred to Teleflex
[5]Teleflex completed the acquisition of substantially all of BIOTRONIK’s Vascular Intervention business effective July 1, 2025.
- 2023
BIOTRONIK Neuro launched
[7]FDA approval of Prospera launched the company’s neuromodulation segment in the United States.
- 2022
Second major U.S. improper-payment settlement
[9]BIOTRONIK Inc. agreed to pay $12.95 million to resolve allegations concerning physician payments, training programs, events, travel, and honoraria.
- 2017
Excellence for Life brand promise adopted
[10]BIOTRONIK adopted “Excellence for Life” as a corporate brand promise and expression of its quality and patient-care positioning.
- 2016
New York Education and Innovation Center opened
[1]BIOTRONIK Inc. opened a training and meeting facility in New York City.
- 2015
CardioMessenger Smart and BioMonitor 2 launched
[1]BIOTRONIK introduced a newer Home Monitoring patient communicator and the second generation of its insertable cardiac-monitor system.
- 2014
Passeo-18 Lux introduced
[1]The company released Passeo-18 Lux, a drug-coated balloon intended for peripheral artery disease in the lower limbs.
- 2014
First major U.S. improper-payment settlement
[8]BIOTRONIK Inc. agreed to pay $4.9 million to resolve U.S. allegations concerning improper payments to physicians.
- 2013
BioMonitor and MRI-compatible device developments
[1]BIOTRONIK launched the BioMonitor implantable ECG-monitoring platform and expanded its ProMRI device portfolio.
- 2012
Postfuhramt building acquired in Berlin
[1]BIOTRONIK acquired the historic Postfuhramt building on Oranienburger Strasse in Berlin.
Products and positioning
A specialist, high-end medical-technology brand focused on active implantable devices, cardiac rhythm management, connected cardiac care, electrophysiology, and neuromodulation. Since 2025, its positioning has placed greater emphasis on active implants and digital health following the divestiture of substantially all of its Vascular Intervention business.
Cardiac rhythm management · 1963
Pacemaker systems
BIOTRONIK’s pacemaker portfolio includes systems for bradycardia therapy, conduction-system pacing, dual-chamber pacing, and cardiac-resynchronization therapy. Product families identified in company and reference materials include Edora, Evity, Enitra, Enticos, Eluna, Epyra, Etrinsa, Evia, Entovis, and related systems. The portfolio is supported by implantable leads, programmers, telemetry, MRI-conditional configurations, and remote monitoring capabilities.
Cardiac rhythm management · 1993
Implantable cardioverter-defibrillators
BIOTRONIK develops implantable cardioverter-defibrillators for the detection and treatment of dangerous ventricular arrhythmias. The company’s ICD history includes the Phylax 06 and later families such as Rivacor, Acticor, Intica NEO, Ilivia, Inventra, Iperia, Idova, and Ilesto. Associated lead systems include Plexa, Linox smart, and Protego. Selected systems are designed for MRI use under specified conditions.
Heart-failure therapy
Cardiac resynchronization therapy systems
The company’s cardiac-resynchronization portfolio includes CRT pacemakers, CRT defibrillators, coronary-sinus leads, lead-delivery systems, and programming tools. The systems are intended to coordinate ventricular contraction in eligible patients with conduction abnormalities and heart failure. Product families include CRT versions of Edora, Evity, Enitra, Enticos, Eluna, Epyra, Etrinsa, Entovis, Evia, Ilivia, Inventra, Iperia, Idova, and Ilesto.
Connected cardiac care · 2000
Home Monitoring
Home Monitoring is BIOTRONIK’s remote patient-monitoring platform for compatible implanted cardiac devices. It transmits device and patient-related information to clinical teams outside scheduled visits, supporting earlier review of arrhythmias, device status, and other clinically relevant events. The platform is a central part of BIOTRONIK’s move toward connected care and digital health.
Remote-monitoring patient device · 2015
CardioMessenger Smart
CardioMessenger Smart is a patient-side communication device used with compatible BIOTRONIK implants and the Home Monitoring service. It helps transmit information from an implanted pacemaker, defibrillator, or other supported cardiac device to the remote-monitoring infrastructure. The product is designed to reduce reliance on routine in-person device checks while keeping clinicians informed about selected device and rhythm events.
Insertable cardiac monitor · 2015
BioMonitor 2
BioMonitor 2 is an insertable cardiac monitor designed for long-term ECG observation and remote transmission of cardiac data. It is used in diagnostic pathways where intermittent symptoms or suspected arrhythmias may not be captured during conventional short-duration monitoring. The product builds on BIOTRONIK’s strategy of combining implanted sensing technology with Home Monitoring and clinician review.
Electrophysiology · 1994
Electrophysiology catheters and systems
BIOTRONIK’s electrophysiology portfolio includes diagnostic catheters, ablation catheters, guidewires, external stimulators, radiofrequency systems, and related equipment. Referenced products include AlCath Flux eXtra Gold, AlCath Flutter, AlCath, ViaCath, Qubic RF, Qubic Stim, Qiona, VisionWire, Streamer, and associated accessories. These systems support the investigation and catheter-based treatment of cardiac rhythm disorders.
Neuromodulation · 2023
Prospera Spinal Cord Stimulation System
Prospera is BIOTRONIK’s FDA-approved spinal cord stimulation system for the management of chronic, intractable pain affecting the trunk or limbs. It uses the RESONANCE stimulation paradigm and is paired with the Embrace One support model, which incorporates remote monitoring and ongoing management support. Prospera was the first product associated with the BIOTRONIK Neuro business segment and is approved in the United States.
Coronary vascular intervention · 2011
Orsiro drug-eluting stent
Orsiro was BIOTRONIK’s major coronary drug-eluting stent family. It used an ultrathin stent platform and a bio-absorbable polymer coating intended to support drug delivery while limiting the persistence of polymer material. Orsiro and Orsiro Mission were among the vascular-intervention products transferred to Teleflex in 2025 and are no longer part of BIOTRONIK’s retained core portfolio.
Coronary drug-coated balloon
Pantera Lux
Pantera Lux was a drug-coated balloon catheter used in coronary intervention. It formed part of BIOTRONIK’s vascular-intervention portfolio and was included among the products transferred to Teleflex when the Vascular Intervention business was acquired effective July 1, 2025.
Covered coronary stent
PK Papyrus
PK Papyrus was a covered coronary stent system designed for selected situations requiring vessel sealing or treatment of coronary perforation. It was part of BIOTRONIK’s coronary-intervention business and transferred to Teleflex in 2025 as part of the Vascular Intervention transaction.
Peripheral drug-coated balloon · 2014
Passeo-18 Lux
Passeo-18 Lux was introduced for peripheral artery disease affecting the lower limbs. It used a drug-coated balloon approach intended to treat narrowed peripheral vessels without leaving a permanent implant at the treatment site. The product and related Passeo families were transferred to Teleflex in 2025.
Controversies
2022
Second U.S. settlement over alleged improper payments
BIOTRONIK Inc. agreed to pay $12.95 million to resolve allegations that it caused false claims to be submitted to federal healthcare programs by providing remuneration to physicians to influence the use of cardiac devices. The allegations included excessive or low-value employee training sessions, lavish meals and events, international business-class travel, and conference honoraria. The Justice Department stated that the claims were allegations only and that the settlement was not a determination of liability.
2014
U.S. settlement over alleged physician kickbacks
The U.S. Department of Justice announced that BIOTRONIK Inc. would pay $4.9 million to resolve False Claims Act allegations that improper payments, expensive meals, and inflated advisory-board compensation were used to induce or reward physician use of BIOTRONIK pacemakers, defibrillators, and cardiac-resynchronization devices. The settlement resolved allegations and did not include an admission or judicial finding of liability.
Marketing campaigns
- 2023BIOTRONIK Neuro launch
United States
The launch of BIOTRONIK Neuro accompanied FDA approval of Prospera and positioned the company in the non-opioid chronic-pain and spinal-cord-stimulation market.
Outcome. The campaign introduced a new business segment and extended BIOTRONIK’s brand beyond cardiovascular therapy.
- 2023EPIC Alliance collaboration
Global electrophysiology community
BIOTRONIK collaborated with the EPIC Alliance, a global network focused on collaboration and support for women electrophysiologists.
Outcome. The collaboration supported professional networking and visibility for women working in electrophysiology.
- 2017Excellence for Life
Global
BIOTRONIK adopted “Excellence for Life” as its corporate brand promise. The platform connected product quality, patient safety, clinical support, and the company’s stated mission of matching technology with the human body.
Outcome. The phrase became part of the company’s visual identity and ongoing corporate communications.
Brand decisions
2025
Refocus on active implants and digital healthStrategyBackground
BIOTRONIK reassessed its portfolio and sought to concentrate resources on businesses most closely related to active implants, connected care, remote monitoring, and digital technologies.
Action taken
The company announced the divestiture of its Vascular Intervention business to Teleflex while emphasizing cardiac rhythm management, digital health, artificial intelligence, remote monitoring, and neuromodulation.
Aftermath
Teleflex completed the acquisition of substantially all of the Vascular Intervention business on July 1, 2025, leaving BIOTRONIK with a more focused active-device and connected-care profile.
2023
Enter neuromodulation with ProsperaProduct launchBackground
BIOTRONIK sought to apply its experience with implanted electrical therapies, remote monitoring, and connected support to chronic-pain treatment.
Action taken
The company obtained U.S. FDA approval for Prospera and launched the BIOTRONIK Neuro business segment.
Aftermath
BIOTRONIK expanded beyond cardiovascular medicine into spinal cord stimulation and non-opioid chronic-pain therapy.
2014
Launch Passeo-18 Lux peripheral drug-coated balloonProduct launchBackground
Peripheral artery disease treatment was moving toward drug-coated balloon technologies intended to reduce restenosis without necessarily leaving a permanent implant.
Action taken
BIOTRONIK released Passeo-18 Lux for peripheral intervention in the lower limbs.
Aftermath
Passeo-18 Lux became part of BIOTRONIK’s peripheral-intervention range and was later transferred to Teleflex.
2011
Launch Orsiro drug-eluting coronary stentProduct launchBackground
BIOTRONIK sought to strengthen its coronary-intervention business with a newer drug-eluting stent platform.
Action taken
The company launched Orsiro, a drug-eluting stent using a bio-absorbable coating and an ultrathin platform.
Aftermath
Orsiro became a prominent part of the company’s vascular-intervention portfolio before its transfer to Teleflex in 2025.
2000
Expand pacemaker telemetry and remote monitoringProduct launchBackground
BIOTRONIK sought to make implanted cardiac devices more informative between scheduled clinical visits.
Action taken
The company introduced the telemetry-enabled Philos pacemaker family and advanced Home Monitoring, including an early implantation connected to remote monitoring.
Aftermath
Remote monitoring became one of BIOTRONIK’s defining technology platforms and a foundation for its later connected-care strategy.
Recent events
BioMonitor IIIm receives 2021 technology leadership award[12]
Biotronik announced that its BioMonitor IIIm implantable cardiac monitor received Frost & Sullivan’s 2021 Enabling Technology Leadership Award.
Acutus Medical and Biotronik announce an international alliance[13]
Acutus Medical and Biotronik announced an alliance to offer a portfolio of electrophysiology mapping, ablation and accessory products for catheter-based treatment of cardiac arrhythmias in select markets, including Europe and Asia.
Sources13 sources
- 1Biotroniken.wikipedia.org
- 2BIOTRONIK Our Historybiotronik.com
- 3BIOTRONIK Imprintbiotronik.com
- 4BIOTRONIK Driving the Future of Active Device Businessbiotronik.com
- 5Change of Ownership – Vascular Intervention Businessbiotronik.com
- 6Teleflex Completes Acquisition of BIOTRONIK’s Vascular Intervention Businessinvestors.teleflex.com
- 7FDA Approval for BIOTRONIK’s Prospera Spinal Cord Stimulation Systembiotronik.com
- 8BIOTRONIK Inc. to Pay $4.9 Million to Resolve Claims that Company Paid Kickbacks to Physiciansjustice.gov
- 9Medical Device Manufacturer Biotronik Inc. Agrees To Pay $12.95 Million To Settle Allegations of Improper Payments to Physiciansjustice.gov
- 10Excellence for Life brand promise adoptedbiotronik.com
- 11EPIC Alliance collaborationbiotronik.com
- 12BioMonitor IIIm 获得 2021 年技术领导力奖dicardiology.com
- 13Acutus Medical与Biotronik宣布国际合作dicardiology.com
Cite this profile: Cite the canonical profile. /brand-wiki/biotronik-se-and-co-kg · Editorial policy · How profiles are compiled